Assembly Biosciences, Inc.
ASMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001426800
No open-market purchases or sales by Assembly Biosciences, Inc. insiders were filed in the last 90 days; 92 institutions reported holding it in 13F filings for Q2 2026, worth $514.8M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Assembly Biosciences, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +3 vs. Q1 2024
- Shares held
- 1.18M
- +523.1K (+80.2%) vs. Q1 2024
- Total value
- $16.1M
- +$7.44M (+85.7%) vs. Q1 2024
- New holders
- 5
- 9 more added
- Sold out
- 2
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ASMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 92 | $514.8M |
| Q1 2026 | 75 | $381.5M |
| Q4 2025 | 69 | $466.7M |
| Q3 2025 | 57 | $324.9M |
| Q2 2025 | 33 | $57.1M |
| Q1 2025 | 37 | $30.4M |
| Q4 2024 | 35 | $50.3M |
| Q3 2024 | 30 | $15.6M |
| Q2 2024 | 27 | $16.1M |
| Q1 2024 | 24 | $8.68M |
| Q4 2023 | 45 | $7.12M |
| Q3 2023 | 32 | $8.62M |
| Q2 2023 | 32 | $12.0M |
| Q1 2023 | 38 | $11.1M |
| Q4 2022 | 40 | $18.4M |
| Q3 2022 | 50 | $27.2M |
| Q2 2022 | 54 | $36.1M |
| Q1 2022 | 54 | $39.3M |
| Q4 2021 | 62 | $54.3M |
| Q3 2021 | 65 | $79.0M |
| Q2 2021 | 91 | $105.1M |
| Q1 2021 | 107 | $133.6M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Assembly Biosciences, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 468,000 | $6.42M | 0.17% | +468,000 | New |
| Vanguard Group Inc | 200,458 | $2.75M | 0.00% | +4,090+2.1% | Added |
| Millennium Management LLC | 123,458 | $1.69M | 0.00% | −1,464−1.2% | Reduced |
| BlackRock Inc. | 77,233 | $1.06M | 0.00% | −728−0.9% | Reduced |
| Renaissance Technologies LLC | 54,911 | $753.4K | 0.00% | +15,451+39.2% | Added |
| Geode Capital Management, LLC | 54,409 | $746.7K | 0.00% | +2,212+4.2% | Added |
| Acuitas Investments, LLC | 49,996 | $685.9K | 0.37% | +264+0.5% | Added |
| Federated Hermes, Inc. | 25,394 | $348.4K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 17,400 | $238.7K | 0.00% | +17,400 | New |
| Bridgeway Capital Management, LLC | 14,500 | $198.9K | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 13,558 | $184.0K | 0.00% | +7,690+131.0% | Added |
| State Street Corp | 12,809 | $175.7K | 0.00% | +700+5.8% | Added |
| Citadel Advisors LLC | 12,746 | $174.9K | 0.00% | +12,746 | New |
| FMR LLC | 12,220 | $167.7K | 0.00% | +902+8.0% | Added |
| Northern Trust Corp | 11,567 | $158.7K | 0.00% | +1,008+9.5% | Added |
| Marquette Asset Management, LLC | 9,016 | $123.7K | 0.02% | 00.0% | Unchanged |
| Amundi | 7,934 | $96.4K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 2,994 | $41.1K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2,949 | $40.5K | 0.00% | −286−8.8% | Reduced |
| Morgan Stanley | 2,562 | $35.2K | 0.00% | −4,854−65.5% | Reduced |
| Tower Research Capital LLC (TRC) | 780 | $10.7K | 0.00% | −77−9.0% | Reduced |
| Rhumbline Advisers | 190 | $2.61K | 0.00% | −9−4.5% | Reduced |
| JPMorgan Chase & Co | 134 | $1.84K | 0.00% | +120+857.1% | Added |
| EverSource Wealth Advisors, LLC | 55 | $803 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 46 | $631 | 0.00% | +46 | New |
| Qube Research & Technologies Ltd | 3 | $41 | 0.00% | 00.0% | Unchanged |
| Frazier Financial Advisors, LLC | 1 | $14 | 0.00% | +1 | New |
| Royal Bank of Canada | 0 | $0 | 0.00% | −79−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −44−100.0% | Sold out |